T he importance of chronic obstructive pulmonary disease (COPD) in health care is increasingly recognised. 1 For a disease that largely affects the elderly smoker, therapeutic nihilism has been prevalent in the past. The combined benefits of smoking cessation, even in established disease, pulmonary rehabilitation, which includes patient empowerment, diseasemodifying medication such as inhaled steroids, long acting β−2 stimulants and anti-cholinergics; and the possible benefit of domiciliary non-invasive ventilation (NIV), offer new hope to a patient group for whom inequitable access to care has been documented. 2 In this editorial, which aims to be deliberately provocative, I will suggest that access to life-saving treatmentintubation in severe respiratory failure -continues to be limited in the UK. In addition to limitation by resource constraints, I believe this arises because of a perception that prognosis is poor -both for survival in the ICU and for subsequent quantity and quality of life. This is partly because doctors regularly confuse quality of life with health status, with resultant withholding of invasive ventilation; partly because predictors of survival are poorly developed; and partly because the very success of NIV in acutely acidotic COPD patients has inadvertently promoted its provision on general medical or respiratory wards where it becomes, by default, the 'ceiling of care. ' An acute exacerbation of COPD (AECOPD) is now the commonest medical reason for hospitalisation in the UK, accounting for up to 10% of all medical admissions. For 50% of these patients, this will be a readmission and in 20%, will be complicated by hypercapnic respiratory failure. 3, 4 For many in this group, the long-term prognosis is poor, with up to 30% being readmitted within three months, whilst those with a raised pCO 2 during admission have a mortality that approaches 50% at one year. 3 On the other hand, for the other 50% it will be a first admission, with a 50-70% chance of survival for 3-5 years. What predictors of outcome are available? Severity of airflow obstruction (FEV 1 ), co-morbidity, especially ischaemic heart disease, severe exercise intolerance and/or dependency in activities of daily living, and a history of recent significant weight loss are all adverse features. The BODE index, which combines body mass index, severity of airflow obstruction, the MRC breathlessness score, and exercise capacity, measured by the six-minute walk, has been promoted as useful for survival prediction. 5 This index, which has only been validated in a US population, predicts a 50% three year survival in the most severe group (Figure 1 ). It has little value in making decisions about intubation in individual situations, for instance, deciding the appropriateness of ICU admission in a 76-year-old house-bound patient, admitted acutely unwell, semi-comatose with severe acidosis (eg pH 7.1 and pC0 2 10 kPa), even if the necessary components of the BODE score are known.
Predicting outcome at the point of need for intubation might be more useful and was the subject of a major study in the US. 6 A predictive model, based on 600 admissions for COPD was first developed and then tested on 400 subsequent admissions, of whom 75% survived to hospital discharge and 75% were still alive at 180 days. Although the model performed reasonably well, with a receiver operator coefficient of 0.75, the SUPPORT study was unable to demonstrate that providing such predictive information, coupled with extensive support to inform and assist patient choice, affected delivery of care. Despite being provided with information on patient preferences and a predictive score, clinicians showed no change in behaviour, and appeared to continue to considerably over-estimate or, alternatively, underestimate survival. 7 Wildman and colleagues, in a series of studies investigating these issues, provide evidence that UK clinicians faced with the decision whether to intubate in COPD patients consistently under-estimate survival. They suggest that in the more resource-limited healthcare system of the UK, clinicians may subconsciously justify the withholding of ICU admission because of this prognostic pessimism. In one report, a telephone simulation study, 8 ICU gatekeepers were asked to make hypothetical admissions decisions in three detailed case scenarios with differing severity. Having made the decision to intubate and admit to ICU or not, respondents were then asked to predict ICU-and 180-day survival if intubation was in fact provided. Not unexpectedly, 'admitters' predicted a higher survival than 'non-admitters' for each scenario. For instance, in the least severe case, admitters predicted 56% versus nonadmitters 23% ICU-survival, and predicted 39% versus 10% 180-day survival. Both groups were more pessimistic than the SUPPORT model predicted, of 90% ICU-survival and 74% 180-day survival.
In a more recent investigation of what Wildman et al term 'prognostic pessimism,' clinicians were asked to estimate the prognosis in real life at the time of ICU admission. Comparison was then made with subsequent outcome. 9 Survival was underestimated, with an increasing disparity between expectation and actual outcome as survival declined (Figure 2 ). In the worst cohort, with 40% survival, clinician expectation of survival was only 10%. In other words, as predicting outcome becomes more important to avoid futile ICU admission when the outlook is poor, clinicians become less skilled and are consistently pessimistic. As a follow-up to this study, survivors were subsequently contacted and questioned about their health and wishes should ICU admission be required at a future date. Seventy-four per cent of respondents reported a quality of life similar, or better, than before being ventilated in the ICU and 96% indicated that they would choose intubation again if required.
The impact of non-invasive ventilation
Non-invasive mask ventilation (NIV) has undoubtedly given more COPD patients access to ventilatory support. It has also affected decision-making when faced with the acidotic COPD patient. In a variety of RCTs, the effectiveness of NIV has been established in preventing the need for intubation and, when used in less severe cases, in reducing progression to a point at which intubation might be necessary.
In a major ward-based UK study, use of NIV reduced the mortality in acidotic AECOPD by 50%. 10 From provision in less than 50% of acute hospitals in 1987, 11 NIV is now available in the vast majority of UK hospitals and training in its application is a core skill for trainees in emergency or respiratory medicine and anaesthesia. What is unclear, however, is how effectively NIV is currently being delivered in the UK.
A recent Royal College of Physicians and British Thoracic Society national audit, as yet only published in abstract, found that only one-third of patients with acidosis actually received NIV, that very few of those who failed NIV progressed to intubation, and that in the majority of cases where ventilatory support was withheld, the reason provided was either lack of facilities or the perception that NIV/intubation and invasive mechanical ventilation was considered 'inappropriate.' 12 Finally, and of major concern, the audit failed to provide evidence that NIV was effective in reducing mortality. The reason for the latter finding is unclear and may in part be confounded by severity of illness. It may also relate to the skills of staff delivering NIV.
It is known that failure to improve with NIV is to be expected in up to 30% of patients, with some patient characteristics aiding patient selection. 13 Our own audit data, collected over the past 10 years, has demonstrated improving effectiveness over time (Figure 3) and indicated the importance of patient selection and placement (ICU when NIV failure likely), the high staff training requirement, and improvements in outcome that may also relate to advances in mask and ventilator design. 
Editorials

Intubation in AECOPD
ICU and hospital survival in AECOPD has historically been reported as between 63% and 86% in a number of case series from the UK, US and Australia. 14 A recent ICNARC UK study reported a 72% hospital survival overall in 3,700 ICU admissions. 15 Not unexpectedly, failure of NIV treatment, the development of other organ failure (particularly renal) and prolonged intubation decrease survival. Overall, therefore, short-term survival of COPD patients selected for ICU admission in the UK is considerably better than for other medical causes for admission. A policy of early extubation employing NIV as a bridge to spontaneous breathing has been shown to be effective 16, 17 . Such a policy will reduce the need for tracheostomy which delays ICU discharge. For those with delayed or failed weaning, eventual tracheostomy decannulation usually proves possible with reports of between 50% 18 and 90% 19 survival to one year in this particularly severe (but selected) group of patients.
Towards an integrated ventilatory strategy in AECOPD
What, then, is an appropriate ventilatory strategy in the acidotic COPD patient? Firstly, it should recognise that survival is to be expected in >75%, and that there are no currently available predictors of sufficient reliability to justify the withholding of intubation when there are contraindications to NIV or when NIV fails. Secondly, there must be close integration between the providers of NIV and ICU gatekeepers to ensure that patients who can benefit from intubation are not excluded by default. Thirdly, the policy should ensure an evidenced-based approach in the ICU, with accelerated extubation to NIV, reserving tracheostomy for those that fail extubation. Finally, I suggest consideration should be given to referral to a specialist weaning centre when the need for mechanical ventilation is prolonged. 20
Withholding ventilation
A decision to withhold treatment such as intubation and the provision of mechanical ventilation is the responsibility of the medical team. Whilst it may be 'good clinical practice' to involve patients or their representatives, 21 this needs to be done with sensitivity, and should primarily be to ascertain preexisting patient' s choice about resuscitation or organ support rather than to seek their involvement in risk/benefit calculation. Health status is the language of the medical team whilst, for patients, quality of life may relate to this only obliquely. Quality of life can be perceived as high despite advanced COPD. The fact that the majority of survivors of an ICU admission after AECOPD would wish intubation again is testament to this fact. It should also be remembered that all communication is value-laden. The description of administration of a paralytic agent followed by intubation and attachment to a ventilator with the risk of subsequent tracheostomy or nosocomial pneumonia can be perceived as 'almost innocuous' to 'horrific' depending upon delivery. Similarly, a 75% chance of failure may make a treatment appear futile to the clinician, whilst a 25% chance of survival may be acceptable, given the alternative, to the patient. Whilst advance directives can be useful, these, by definition, involve decisions made following discussion and reflection and cannot satisfactorily be made at times of crisis. Experience in supporting COPD patients in making intubation decisions indicates that it requires multiple discussions, that the process can be emotionally painful and that even in advanced disease only a proportion of patients choose to limit treatment. 22 In conclusion, I propose that the default position should be intubation for all acidotic AECOPD patients requiring ventilatory support if a trial of NIV is contraindicated or, for the majority, if NIV fails to improve respiratory status. ICU admission would only be withheld if there was either a valid advance directive or if, following discussion, there was agreement by an intensivist and the senior clinician responsible for the patient that ICU admission would be medically futile. Such a policy would increase the number of patients receiving therapeutic NIV or ICU admission by as much as three-fold and would therefore have significant resource implications. For the success of such a policy it would be necessary to ensure the care of advanced COPD is recognised as requiring specialist skills and knowledge. All patients admitted with AECOPD should be reviewed by the respiratory team and, when health status is poor and considered irreversible, discussion about possible limits to future care should be initiated by those with appropriate skills. There is good evidence that access to ventilatory support in AECOPD is currently inequitable, and that a comprehensive service is available in few hospitals. However, to not develop an integrated ventilator strategy for the acidotic AECOPD patient in the face of the evidence could be perceived as medical discrimination.
